Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 11/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | ASF1A | Q9Y294 | 2/20 | 0.61 |
| ▸ | MIF | P14174 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23752358 | 0.90 | SIRT1 (0.83) | SIRT1KMT2AMAPTMEN1KDM4E | |
| SCHEMBL23752360 | 0.90 | SIRT1 (0.83) | SIRT1KMT2AMAPTMEN1KDM4E | |
| SCHEMBL8289596 | 0.87 | SIRT1 (0.61) | SIRT1KMT2AMAPTMEN1KDM4E | |
| SCHEMBL6571360 | 0.79 | MAPT (0.74) | KMT2AMAPTMEN1KDM4EMIF | |
| SCHEMBL6571363 | 0.79 | MAPT (0.74) | KMT2AMAPTMEN1KDM4EMIF | |
| SCHEMBL28423171 | 0.79 | MAPT (0.74) | KMT2AMAPTMEN1KDM4EMIF | |
| SCHEMBL7949340 | 0.78 | KMT2A (0.78) | SIRT1KMT2AMAPTMEN1KDM4E | |
| SCHEMBL7949337 | 0.78 | KMT2A (0.78) | SIRT1KMT2AMAPTMEN1KDM4E | |
| SCHEMBL8289493 | 0.78 | KMT2A (0.57) | SIRT1KMT2AMAPTMEN1KDM4E | |
| SCHEMBL683742 | 0.77 | KMT2A (0.69) | SIRT1KMT2AMAPTMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263636-B2 | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases | IMTM GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-8263636-B2 | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases | IMTM GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| EP-2105441-A1 | Alanyl aminopeptidase and dipeptidylpeptidase IV dual inhibitors for the treatment of immunological, inflammatory, neuronal and other illnesses | IMTM GmbH (DE) | 2009-09-30 | — | — | EP | disclosed |
| US-20070078130-A1 | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-04-05 | — | — | US | disclosed |
| US-20070078130-A1 | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-04-05 | — | — | US | disclosed |
| US-20070037752-A1 | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037752-A1 | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| WO-2005037257-A2 | NOVEL ALANYL-AMINO PEPTIDASE INHIBITORS FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AND OTHER DISEASES | IMTM GMBH (DE) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005034940-A2 | DUAL ALANYL AMINOPEPTIDASE AND DIPEPTIDYL PEPTIDASE IV INHIBITORS FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND FOR TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL AND OTHER DISEASES | IMTM GMBH (DE) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078130-A1 | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases | DNPEP, PREP, ANPEP | SIRT1 3974/4885KMT2A 3636/4885MAPT 1296/4885 |
| US-20070037752-A1 | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | DNPEP, PREP, ANPEP | SIRT1 4153/4885KMT2A 3390/4885MAPT 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.